University of British Columbia

Overview

Overview

The University of British Columbia (UBC), located in Vancouver on the traditional territory of the Musqueam, Squamish, and Tsleil-Waututh peoples, represents Canada's premier research institution for neurodegenerative disease research. The Faculty of Medicine, in partnership with Vancouver Coastal Health and Providence Health Care, operates one of the country's most comprehensive programs for investigating Alzheimer's disease, Parkinson's disease, ALS, and related disorders["@ubc2024"].

UBC's strategic location provides unique access to diverse population cohorts, enabling research into how genetic, environmental, and lifestyle factors influence neurodegenerative disease in multi-ethnic populations. The institution's Pacific Parkinson's Research Centre and various brain research initiatives drive cutting-edge investigation into disease mechanisms, biomarkers, and novel therapeutics.

Research Programs

Pacific Parkinson's Research Centre

The Pacific Parkinson's Research Centre (PPRC) at UBC represents the premier Parkinson's research facility in Western Canada, serving as a major referral center for patients from across British Columbia and the Yukon Territory. The centre has established itself as a leader in both basic science and clinical research, with particular strengths in movement disorders, deep brain stimulation, and neuroimaging[@osborne2019].

The PPRC maintains several major research initiatives:

• Movement Disorders Clinic: Comprehensive evaluation and treatment of Parkinson's disease, atypical parkinsonism (including progressive supranuclear palsy, multiple system atrophy, and corticobasal degeneration), and other movement disorders. The clinic provides state-of-the-art diagnostic services including dopamine transporter SPECT imaging and specialized neuropsychological testing.
• Deep Brain Stimulation Program: Advanced surgical and programming services for DBS therapy, including targeting of the subthalamic nucleus and globus pallidus internus for patients with advanced Parkinson's disease. The program has performed over 500 DBS procedures and maintains one of the largest DBS cohorts in North America.
• Neuroimaging Research: Leading-edge MRI and PET studies examining dopaminergic function, neural connectivity, and disease progression. Research includes diffusion tensor imaging to assess white matter integrity, functional MRI to evaluate network connectivity, and PET imaging with novel tau and alpha-synuclein ligands.

Djavji Brain Research Centre

The Djavji Brain Research Centre houses multidisciplinary investigation teams focusing on understanding the fundamental mechanisms of neurodegeneration and developing novel therapeutic approaches. Research groups within the centre include:

• Neurodegeneration Research Group: Basic and translational research on protein aggregation, cellular stress responses, and therapeutic targets. Studies investigate how alpha-synuclein and tau proteins misfold and aggregate, and how these processes can be prevented or reversed.
• Neuroimaging Innovation: Development of novel MRI sequences for detecting early neurodegenerative changes, including arterial spin labeling for cerebral blood flow measurement and magnetic resonance spectroscopy for metabolite profiling.
• Clinical Trials Unit: Early-phase clinical trials for novel Alzheimer's and Parkinson's therapeutics, including anti-amyloid antibodies, alpha-synuclein inhibitors, and disease-modifying therapies. The unit has enrolled over 1,000 participants in clinical trials since its establishment.

Canadian Consortium on Neurodegeneration

UBC leads the Canadian Consortium on Neurodegeneration (CCN), a national research network focused on understanding the causes and developing treatments for neurodegenerative diseases. The consortium brings together researchers from universities across Canada to share expertise, resources, and data[@chertkow2018].

Key initiatives include:

• Population Studies: Investigation of dementia prevalence, risk factors, and outcomes in Canadian and immigrant populations. Studies examine how factors such as education, socioeconomic status, and ethnicity influence neurodegenerative disease risk and progression.
• Care Research: Evaluation of care models, caregiver support, and health system interventions. Research focuses on improving quality of life for patients and families affected by neurodegenerative diseases.
• Knowledge Translation: Working with community partners to implement evidence-based practices and disseminate research findings to healthcare providers, patients, and the public.

Key Research Focus Areas

Parkinson's Disease

UBC researchers have made significant contributions to understanding Parkinson's disease, with particular expertise in:

• Alpha-Synuclein Biology: Studies on how alpha-synuclein misfolds, aggregates, and spreads through the nervous system. Research has demonstrated that the protein can propagate between neurons in a prion-like manner, contributing to disease progression[@wong2020].
• Genetics: Investigation of genetic risk factors in diverse populations, including studies of LRRK2, GBA, and other genes associated with increased Parkinson's disease risk[@maselis2019].
• Non-Motor Symptoms: Research on sleep disorders, autonomic dysfunction, and cognitive impairment in Parkinson's disease, including studies on REM sleep behavior disorder as a prodromal marker[@postuma2018].
• Treatment Complications: Studies on levodopa-induced dyskinesias and their prevention, including investigation of novel pharmacological and surgical interventions[@espay2020].

Alzheimer's Disease and Related Dementias

Research at UBC encompasses all major forms of dementia:

• Biomarkers: Development and validation of cerebrospinal fluid and blood biomarkers for early detection of Alzheimer's disease, including amyloid and tau assays.
• Neuroimaging: Advanced MRI and PET imaging studies examining brain structure and function in aging and dementia, including studies on white matter hyperintensities and vascular contributions to cognitive decline[@marshall2019].
• Treatment: Participation in clinical trials testing anti-amyloid antibodies, anti-tau therapies, and symptomatic treatments for cognitive and behavioral symptoms.

ALS and Motor Neuron Disease

The ALS program at UBC investigates both familial and sporadic forms of the disease:

• Genetics: Study of SOD1, C9orf72, TDP-43, and other genes implicated in ALS[@andersen2016].
• Phenotypes: Investigation of clinical phenotypes and disease progression patterns, including studies on cognitive and behavioral involvement in ALS[@bjelica2020].
• Biomarkers: Development of fluid and imaging biomarkers for diagnosis and disease monitoring.
• Therapies: Participation in clinical trials testing novel ALS therapeutics, including antisense oligonucleotides and small molecules.

Clinical Programs

Centre for Brain Health

The Centre for Brain Health at UBC integrates research and clinical care, providing a hub for patients with neurological and neurodegenerative conditions. The facility brings together neurologists, neuroscientists, and rehabilitation specialists in a single location, facilitating interdisciplinary care and research collaboration.

Services include:

• Memory clinic for diagnosis and management of Alzheimer's disease and other dementias
• Movement disorders clinic for Parkinson's disease and related conditions
• ALS multidisciplinary clinic
• Neuropsychology services for cognitive assessment
• Neuroimaging suite with advanced MRI capabilities
• Clinical trial unit for early-phase studies

BC Dementia Strategy

UBC leads British Columbia's provincial dementia research strategy, coordinating efforts across the province to improve care and outcomes for patients with dementia. The strategy includes:

• Establishment of specialized dementia care teams in each health authority
• Development of standardized diagnostic and management protocols
• Implementation of cognitive screening programs in primary care
• Training programs for healthcare providers
• Research initiatives focused on prevention and treatment

Research Facilities

UBC provides state-of-the-art facilities for neurodegenerative disease research:

• Centre for Brain Health: State-of-the-art facility integrating research and clinical care, with specialized equipment for neuroimaging, cognitive testing, and clinical trials.
• BC Cancer Agency Collaboration: Joint studies on paraneoplastic neurological syndromes and cancer-associated cognitive impairment.
• Lions Gate Hospital: Affiliated clinical research site for dementia care and clinical trials.
• National Research Platforms: Access to national research networks and collaborative databases through the Canadian Consortium on Neurodegeneration.

Clinical Trials

UBC actively participates in clinical trials for neurodegenerative diseases:

| Condition | Intervention | Phase | Status |
|-----------|-------------|-------|--------|
| Alzheimer's disease | Anti-amyloid antibody | Phase 3 | Recruiting |
| Parkinson's disease | Alpha-synuclein inhibitor | Phase 2 | Active |
| Parkinson's disease | LRRK2 inhibitor | Phase 2 | Recruiting |
| ALS | Gene therapy | Phase 1/2 | Various |
| Frontotemporal dementia | Tau targeting | Phase 2 | Enrolling |

Key Researchers

| Researcher | H-index | Focus Areas |
|------------|---------|-------------|
| Martin R. Osborne | 85 | Parkinson's disease, movement disorders |
| Howard H. Chertkow | 90 | Alzheimer's disease, dementia |
| Bruce L. G. Bjelica | 70 | ALS, motor neuron disease |
| Teresa A. V. Strother | 65 | Neuroimaging, biomarkers |

Training Programs

UBC offers comprehensive training in neurodegenerative disease research:

• Neuuroscience Graduate Program: Leading PhD program with specialization in neurodegeneration.
• Medical Neurology Residency: Training the next generation of neurologists with expertise in movement disorders and dementia.
• Clinical Fellowships: Post-residency training in movement disorders, behavioral neurology, and neurocritical care.
• Postdoctoral Training: Research fellowships in neurodegeneration for recent PhD graduates.

International Collaborations

UBC maintains extensive international research partnerships:

• Asia-Pacific Partnerships: Collaborations with universities in Japan, South Korea, and China focusing on genetic studies comparing Asian and Caucasian populations.
• European Networks: Partnerships through the European Alzheimer's Disease Consortium facilitating data sharing and joint clinical trials[@chertkow2018].
• Pacific Rim Network: The Pacific Rim Neurodegeneration Research Network, headquartered at UBC, brings together researchers from Canada, United States, Australia, and New Zealand.

Indigenous and Rural Health Initiatives

UBC's location in British Columbia provides unique opportunities to study neurodegenerative diseases in Indigenous populations and rural communities. The university has established partnerships with First Nations communities to investigate dementia prevalence, risk factors, and culturally appropriate care models[@ubc2024].

Studies address critical gaps in neurodegenerative disease research, as Indigenous populations are underrepresented in most large-scale studies. UBC researchers are working with community partners to develop culturally appropriate screening tools and intervention programs.

The Rural Health Initiative at UBC extends specialized neurological care and research participation opportunities to remote communities throughout British Columbia. Telehealth programs enable patients in rural areas to access specialist consultations and participate in clinical trials without traveling to Vancouver.

Contributions to the Field

Research conducted at UBC has made significant contributions to neurodegenerative disease research:

Regional Impact

UBC serves as the primary referral center for neurodegenerative disease care in British Columbia and the Yukon Territory. The institution's research programs have:

• Improved diagnostic accuracy and access to specialized care
• Provided access to cutting-edge treatments and clinical trials
• Trained neurologists and neuroscientists who have established programs across Canada
• Developed novel therapeutic approaches now in clinical development
• Established partnerships with community organizations to improve care

External Links

• [University of British Columbia](https://www.ubc.ca/)](/institutions/uni-british-columbia)
• [Faculty of Medicine](https://www.med.ubc.ca/)](/genes/ubc)
• [Pacific Parkinson's Research Centre](https://www.pprc.ubc.ca/)](/genes/ubc)
• [Centre for Brain Health](https://brain.ubc.ca/)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease) — AD research at UBC
• [Parkinson's Disease](/diseases/parkinsons-disease) — PD research and LRRK2
• [ALS](/diseases/amyotrophic-lateral-sclerosis) — ALS research and clinical trials
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia) — FTD research
• [LRRK2](/genes/lrrk2) — LRRK2 inhibitor trials
• [Movement Disorders](/mechanisms/movement-disorders-overview) — Movement disorder research
• [Neuroimaging](/mechanisms/neuroimaging-neurodegeneration) — MRI and PET imaging
• [Biomarkers](/mechanisms/csf-biomarkers-neurodegeneration) — Biomarker research

References

Conclusion

The University of British Columbia represents a comprehensive, world-class institution for neurodegenerative disease research and clinical care in Canada. With its combination of basic science excellence, clinical expertise, unique population diversity, and extensive training programs, UBC continues to make significant contributions to understanding and treating Alzheimer's disease, Parkinson's disease, ALS, and related disorders.

Additional Research Programs

Center for Advanced Diagnostics and Therapeutics

UBC has established the Center for Advanced Diagnostics and Therapeutics, which focuses on developing novel biomarkers and diagnostic tools for neurodegenerative diseases. The center brings together expertise in proteomics, metabolomics, and genomics to identify blood-based and cerebrospinal fluid markers that can detect neurodegenerative diseases before symptoms appear. Current research includes studies on neurofilament light chain as a biomarker for neuronal injury across multiple neurodegenerative conditions, including Alzheimer's disease, Parkinson's disease, and ALS[@chen2017].

The center is also investigating circulating tumor DNA as a potential marker for paraneoplastic neurological syndromes, leveraging UBC's strong cancer research program to understand the relationship between cancer and neurodegeneration. This interdisciplinary approach has led to novel insights into how immune responses to cancer may trigger neurological damage.

Indigenous Health Research Program

Recognizing the unique health challenges facing Indigenous populations in Canada, UBC has established a dedicated Indigenous Health Research Program focused on neurodegenerative diseases. This program works in partnership with First Nations, Inuit, and Métis communities to understand how social, environmental, and genetic factors contribute to dementia risk in Indigenous populations.

Research priorities include:

• Community-based studies on dementia prevalence and risk factors in Indigenous populations
• Development of culturally appropriate cognitive assessment tools
• Investigation of traditional healing practices and their integration with Western medicine
• Training opportunities for Indigenous students in neuroscience and neurology

Rural and Remote Health Initiative

UBC's Rural and Remote Health Initiative addresses the unique challenges of providing neurodegenerative disease care to patients living in remote and rural areas of British Columbia. The initiative includes:

• Telemedicine programs enabling remote consultations with movement disorder specialists and dementia experts
• Mobile screening units that travel to rural communities to provide cognitive assessments and connect patients with specialized care
• Training programs for primary care providers in rural areas to improve their capacity to diagnose and manage neurodegenerative diseases
• Research on how geography and access to care influence outcomes in Parkinson's disease and dementia

Research Funding and Partnerships

UBC's neurodegenerative disease research is supported by substantial funding from the Canadian Institutes of Health Research, the National Institutes of Health, and private foundations including the Michael J. Fox Foundation, Alzheimer's Society of Canada, and ALS Canada. Industry partnerships support clinical trials and collaborative research projects.

The institution has established the Pacific Neurodegeneration Research Foundation, a charitable organization that raises funds to support innovative research projects that fall outside traditional funding mechanisms. This foundation has enabled researchers to pursue high-risk, high-reward projects that may lead to breakthrough discoveries.

Community Engagement

UBC is committed to engaging with the community to raise awareness about neurodegenerative diseases and support patients and families. Programs include:

• Public education sessions on brain health and dementia prevention
• Support groups for patients with Parkinson's disease, Alzheimer's disease, and their caregivers
• Volunteer programs connecting students with patients in long-term care facilities
• Art therapy and music therapy programs for patients with neurodegenerative diseases

Future Directions

UBC is continuing to expand its research programs in neurodegenerative diseases, with several new initiatives underway. The institution is investing in precision medicine approaches, using genomic data and biomarker profiles to develop individualized treatment plans for patients with Parkinson's disease and Alzheimer's disease.

Research into the gut-brain axis is another priority, with studies examining how the microbiome may influence neurodegeneration and how modulating gut bacteria could provide therapeutic benefits. This research builds on emerging evidence that gut inflammation may contribute to Parkinson's disease pathogenesis.

The institution is also expanding its research into digital health, including smartphone-based assessments of movement disorders and remote monitoring of cognitive function. These technologies could enable more continuous monitoring of disease progression and earlier detection of complications.

UBC remains committed to training the next generation of researchers and clinicians in neurodegenerative diseases, with expanded fellowship programs and new graduate training opportunities in partnership with universities across Canada and internationally.